Table 4.

Multivariable Analysis Results of Short Stature, Obesity and Gonadotropin Deficiency (LH/FSHD) for Patients with and without CPP

	Short Stature (n=63)			Obesity (n=63)			LH/FSHD* (n=63)
	N (%)μ	OR (95%CI)	p	N (%)μ	OR (95%CI)	p	N (%)μ	OR (95%CI)	p
CPP
No	4 (12.1)	1.00		12 (36.4)	1.00		12 (36.4)	1.00
Yes	6 (20.0)	1.37 (0.27–6.97)	0.70	14 (46.7)	1.54 (0.46–5.14)	0.48	12 (40.0)	0.69 (0.19–2.57)	0.58
Age at tumor diagnosis
<5 years	8 (25.0)	1.00		14 (43.8)	1.00		15 (46.9)	1.00
≥5 years	2 (6.5)	0.16 (0.03–1.03)	0.05	12 (38.7)	0.91 (0.31–2.68)	0.86	9 (29.0)	0.36 (0.10–1.25)	0.11
GHD
No	2 (11.1)	1.00		4 (22.2)	1.00		-	-	-
Yes	8 (17.8)	0.24 (0.02–3.12)	0.27	22 (48.9)	3.73 (0.57–24.50)	0.17	-	-	-
Type-1 neurofibromatosis
No	9 (16.4)	1.00		24 (43.6)	1.00		23 (41.8)	1.00
Yes	1 (12.5)	0.28 (0.02–3.78)	0.34	2 (25.0)	0.32 (0.05–1.99)	0.22	1 (12.5)	0.11 (0.01–1.17)	0.07
Cranial radiotherapy
No	1 (5.9)	1.00		5 (29.4)	1.00		1 (5.9)	1.00
Yes	9 (19.6)	10.32 (0.46–233.71)	0.14	21 (45.7)	0.72 (0.11–4.68)	0.73	23 (50.0)	22.35 (2.44–204.90)	0.006

CPP= Central precocious puberty, GHD= GH deficiency.

^*GHD was not included into the model since none of the patients without GHD had LH/FSHD..

μ: row percent.